Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Abstract

Purpose: Different definitions of progression-free survival (PFS) and event-free survival (EFS) may result in perceived differences in outcomes with tyrosine kinase inhibitor (TKI) therapies in chronic myelogenous leukemia (CML).

Patients and methods: We analyzed the outcome of 435 patients with early chronic-phase, Philadelphia chromosome-positive CML treated with imatinib (n = 281), nilotinib (n = 78), and dasatinib (n = 76) using definitions of PFS and EFS used in the International Randomized Study of Interferon Versus STI571 (IRIS), Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENEST-nd), Dasatinib Versus Imatinib Study in Treatment-Naïve CML Patients (DASISION), and MD Anderson Cancer Center (MDACC) trials. Definitions for EFS-IRIS, time without progression in ENEST-nd, PFS-DASISION, and EFS-MDACC were as previously reported. The EFS-MDACC considered an event any instance of toxicity or death from any cause on or off therapy (if not counted before death as progression/event).

Results: Of the 435 patients, 123 (28%) were taken off TKI therapy (resistance/loss of response, n = 33; blastic phase on TKI therapy, n = 6; intolerance/toxicity, n = 29; other causes, n = 55). Thirty-three patients (7.6%) have died; eight patients died on TKI therapy, two patients died within 60 days of being off TKIs, and 23 patients died after being off TKIs for more than 60 days. Of the 33 deaths, 19 deaths (eight deaths on TKI, two deaths within 60 days, and nine deaths off for resistance/relapse/transformation) would be counted as progression/events on the IRIS/ENEST-nd/DASISION studies, whereas 14 deaths would be censored at time off TKI. On the basis of the four definitions used by IRIS, ENEST-nd, DASISION, and MDACC trials, the corresponding 5-year PFS/EFS rates were 96%, 90%, 89%, and 81%.

Conclusion: Uniform definitions of PFS and EFS are needed to compare the long-term efficacy and potential use of different TKIs in CML.

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.

(A) Overall survival by treatment and (B) survival without blastic phase (events = death from any cause or blastic phase) in patients with chronic myeloid leukemia overall and by therapy. TKI, tyrosine kinase inhibitor.

Fig 2.

Outcome according to different reported definitions. DASISION, Dasatinib Versus Imatinib Study in Treatment-Naïve CML Patients; EFS, event-free survival; ENEST-nd, Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients; IRIS, International Randomized Study of Interferon Versus STI571; MDACC, MD Anderson Cancer Center; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; TWP, time without progression; yr, year.

Fig 3.

Outcome according to different definitions in the 281 patients treated with imatinib. DASISION, Dasatinib Versus Imatinib Study in Treatment-Naïve CML Patients; EFS, event-free survival; ENEST-nd, Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients; IRIS, International Randomized Study of Interferon Versus STI571; MDACC, MD Anderson Cancer Center; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; TWP, time without progression; yr, year.